NeuroOne Medical Technologies

NeuroOne Medical Technologies FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of NeuroOne Medical Technologies (NMTC) as of Oct 28, 2026 is 80.96 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 90.37 % — a change of -10.41% (lower).

FCF Conversion

80.96 %

YoY

-10.41%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of NeuroOne Medical Technologies is 2025 80.96 % . FCF Conversion Rate (FCF/EBITDA) of NeuroOne Medical Technologies was 2024 90.37 % . It decreases by -10.41% lower compared to the previous year.

The NeuroOne Medical Technologies FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
42.76 USD
Jan 1, 2019
81.39 USD
Jan 1, 2020
26.01 USD
Jan 1, 2021
87.15 USD
Jan 1, 2022
77.95 USD
Jan 1, 2023
111.90 USD
Jan 1, 2024
90.37 USD
Jan 1, 2025
80.96 USD
The NeuroOne Medical Technologies FCF Conversion history
YEARFCF ConversionYoY
80.96 %-10.41%
90.37 %-19.24%
111.90 %+43.55%
77.95 %-10.56%
87.15 %+235.07%
26.01 %-68.04%
81.39 %+90.33%
42.76 %-81.89%
236.14 %+67.58%
140.91 %+95.13%
72.21 %-12.07%
82.13 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

NeuroOne Medical Technologies Stock analysis

What does NeuroOne Medical Technologies do? NeuroOne Medical Technologies Corp., based in Eden Prairie, Minnesota, develops and commercializes thin film electrode technology for medical applications. The company focuses on continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording, spinal cord stimulation, brain stimulation, and ablation solutions for neurological disorders such as epilepsy, Parkinson's disease, and chronic pain. Listed on the stock market in 2012, NeuroOne employs 15 people and explores AI applications in its technology. NeuroOne Medical Technologies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about NeuroOne Medical Technologies stock

FCF Conversion Rate (FCF/EBITDA) of NeuroOne Medical Technologies is 80.96 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of NeuroOne Medical Technologies changed from 90.37 % to 80.96 %, representing a -10.41% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) NeuroOne Medical Technologies since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s NeuroOne Medical Technologies with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — NeuroOne Medical Technologies

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — NeuroOne Medical Technologies